Vertex Stock Surges on FDA Approval of Non-Opioid Painkiller

Vertex Pharmaceuticals' stock price surged on Friday, January 31, 2025, following the U.S. Food and Drug Administration's (FDA) approval of the company's non-opioid painkiller, Journavx. The drug, a first-of-its-kind oral treatment for moderate-to-severe acute pain, is expected to revolutionize the pain management market and provide a much-needed alternative to addictive opioid medications.